Developing therapeutics for diseases with impaired kidney function

ENYO Pharma is a clinical-stage biopharmaceutical company.

Our mission is to develop highly differentiated therapeutics for improving the quality of life of patients with impaired kidney function.

Our lead clinical compound VONAFEXOR is a small molecule with strong fibrolytic and anti-inflammatory properties in both organs, kidney and liver.
It is currently in Phase 2 development for rare kidney disease Alport Syndrome and Chronic Kidney Diseases (CKD).

Latest Press Release

ENYO Pharma announces a €39 million Series C financing and FDA clearance to advance Vonafexor in a Phase 2 clinical trial for patients with Alport syndrome. > Read more

Executive Team

ENYO Pharma’s team is world class with a crucial mix of pharma senior leadership and scientific excellence in biology and drug development to bring the company forward.

> Read more

Pipeline

ENYO Pharma is advancing its pipeline with Vonafexor series for diseases with impaired kidney function as CKD, Alport syndrome, NASH and DKD.

> Read more

Next Event

.

> Read more
© 2020 ENYO Pharma SA